Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Provided By GlobeNewswire
Last update: Aug 7, 2025
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26
Read more at globenewswire.com
